Medi Caps (523144)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Looking at Medi Caps, I'm reminded that a low price-to-book is not by itself a bargain. The stock trades at ₹48.57, below book value of ₹58.60, so the market is offering this business at 83 paise per rupee of net assets. But a Benjamin Graham disciple must ask: can these assets generate earnings? The latest quarter tells a troubling story: sales of just ₹4 Cr and a net loss of ₹1 Cr. Full-year ROE is a meager 1.30% and ROCE is negative at -2.12%, meaning operating capital is destroying value, not creating it. A P/E of 0.00 confirms that current earnings are essentially absent. There is 6.97% sales growth and reported profit growth of 62.44%, but with such a small base and a loss in the latest quarter, I would not anchor on that figure. The Piotroski F-score of 6/9 gives me some comfort that the financial position is not collapsing, yet I need to know much more about debt, promoter holding, and why earnings are so weak. At a ₹61 Cr market cap, this is a micro-cap in a competitive pharma world; a durable moat is not visible from these numbers. If assets are genuinely worth ₹58.60 and can be unlocked, this could be an asset play. But if those assets earn poor returns, book value can erode. I would need a long track record of cash generation and honest capital allocation before committing. For now, it is a possible asset-backed opportunity, not a wonderful compounder.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer